Delivery Order SPE2DB22D1002-SPE2DB24FLBK3
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of QULIPTA 60 MG TABLET 30S, a medication, with a ceiling value of $28,102.43 and a completion date of June 30, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of QULIPTA 60 MG TABLET 30S. The contract has a firm fixed-price, delivery order type with a ceiling value of $7,831.62 and a performance period ending on January 15, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,279.87 firm fixed price contract is for the delivery of QULIPTA 60 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of June 11, 2025 and is not set aside for any special business category. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,529.40 firm fixed-price contract is for the supply of QULIPTA 30 MG TABLET 30S, a pharmaceutical product. The award has an ultimate completion date of July 8, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999.00. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,302.13 firm fixed-price delivery order is for the provision of QULIPTA 60 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of March 21, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the procurement of QULIPTA 60 MG TABLET 30S. The $9,687.83 Firm Fixed Price Delivery Order contract has an ultimate completion date of January 17, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of QULIPTA 30 MG TABLET 30S. The contract is a firm-fixed-price delivery order with a ceiling value of $1,116.21 and an ultimate completion date of September 6, 2024. This award is not a set-aside contract. Amerisourcebergen, through its Corporate Office division, has been a significant supplier of pharmaceutical products and medical supplies...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,830.29 firm fixed-price delivery order is for the supply of QULIPTA 30 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of July 3, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,460.62 firm fixed-price delivery order is for the supply of QULIPTA 60 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 13, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of QULIPTA 30 MG TABLET 30S. The contract has a ceiling value of $1,154.79 and a completion date of May 16, 2025. AmerisourceBergen Drug Corporation holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB24FLBK3Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical and medical supply distributor, for the delivery of QULIPTA 30 MG TABLET 30S. The contract, awarded on April 29, 2024, has a ceiling value of $1,116.21 and an ultimate completion date of May 20, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. Amerisourcebergen also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 4/29/24 |